Moderna (MRNA) Current Assets (2017 - 2026)

Moderna has reported Current Assets for 10 years, with the latest figure at $5.8 billion in Q2 2026.

• Current Assets for Q2 2026 came in at $5.8 billion, down 5.77% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.8 billion (down 5.77% YoY), and the FY2025 annual result was $6.5 billion, down 19.2% from the prior year.
• Current Assets rose to $5.8 billion in Q2 2026, from $5.8 billion in the prior quarter.
• Over five years, Current Assets peaked at $16.4 billion in Q1 2022 and troughed at $5.8 billion in Q1 2026.
• A 5-year average of $9.8 billion and a median of $9.7 billion in 2024 frame the typical range for Current Assets.
• The widest annual swing landed in 2022, when Current Assets surged 39.71%; it then tumbled 36.12% in 2025.
• A 5-year view of Current Assets shows it stood at $13.4 billion in 2022, then retreated by 23.13% to $10.3 billion in 2023, then decreased by 21.56% to $8.1 billion in 2024, then declined by 19.2% to $6.5 billion in 2025, then dropped by 11.14% to $5.8 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $5.8 billion in Q2 2026, $5.8 billion in Q1 2026, and $6.5 billion in Q4 2025.